Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Neuro-Bio is a start-up company focused on the development of novel, effective therapeutics for neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Motor Neuron Disease. The Company’s uniqueness lies in its innovative identification of the initial trigger of neurodegeneration - this has been developed throughout Baroness Professor Susan Greenfield’s highly credited 40 year career in neuroscience.

Cellix Bio Pvt Ltd. is a biopharmaceutical company, which engages in the development and discovery of novel drugs. It specializes in the treatment of neurology, dermatology, gastrointestinal, inflammation, metabolic and life style, oncology, ophthalmology, and infectious diseases. The company was founded by Mahesh Kandula on May 21, 2014 and is headquartered in Hyderabad, India.

J2H Biotech, Inc. is engaged in the manufacturing of Medicinal Chemicals and Antibiotics. The company was founded on October 1, 2014 and is headquartered in Suwon-si, South Korea.

THERAGEN ETEX Co., Ltd. engages in the manufacture and sale of pharmaceutical products and in the provision of genome sequencing services. It operates through the following business divisions: Pharmaceutical, Specialized drug distribution, Healthcare and Genome. It offers cimetidine tabs, dimetal tabs, gabamin tabs, aclfen tab, hydone tab, other pharmaceutical products and genome analysis services. The company was founded on September 27, 1990 and is headquartered in Ansan-si, South Korea.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

QurAlis is a clinical-stage biotechnology company that is developing precision medicines with genetically validated targets for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its proprietary platforms and biomarkers allow for the design and development of drugs that target disease-causing genetic alterations directly.

4D Pharma Research Ltd., a subsidiary of 4D Pharma Plc, is a company headquartered in Aberdeen, UK, that engages in research and experimental development on biotechnology.

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs. It seeks to solve challenges in health with science, to help people live healthier and longer lives. It works directly with the scientists, clinicians, and health professionals around the world to identify and develop the natural compounds. Its product is a proprietary formulation of two ingredients designed to support long-term well-being at the cellular level.

NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes: (1) StabiliC for the treatment of Parkinson's disease and (2) CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

GliaPharm is a Swiss-based biotechnology company that offers treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic approach is to target glial cells , the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Their vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions. GliaPharm is a Swiss biotechnology company active in the development of treatments for neurological and psychiatric diseases. The innovative therapeutic approach of GliaPharm is to target glial cells , or 'support cells' of neurons, to support and improve brain metabolism under certain pathological conditions. Their vision is to become a leader in the development of glial cell targeting agents that act as neuroprotective agents and maintain cognitive functions.

BenevolentAI Bio Ltd. (doing business as Benevolent Bio Ltd.), a subsidiary of BenevolentAI SA, is a company headquartered in London, UK. The firm engages in development and application of artificial intelligence. It was founded in 2013.

Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. It develops ICA-105665 that is in Phase I single dose escalation study in healthy volunteers for epilepsy and neuropathic pain; and Senicapoc, which is in Phase I multiple dose study in healthy volunteers for the treatment of asthma. The company also conducts ongoing drug discovery programs on new therapeutics for pain and inflammatory disorders. Icagen has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma, Inc.; and Pfizer, Inc.

Hunter-Fleming Ltd. dvelops pharmaceutical products. The company was founded by James R. Murray, John S. Fox and Ernst Wülfert in February 1999 and is headquartered in Brixham, the United Kingdom.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.